Table 3.
Samples used for specificity panel and cross-reactivity results. Numbers indicate equivocal and positive results for each assay
| Specificity panel (sample number) | MAGLUMI 2000 plus 2019-nCov IgM | MAGLUMI 2000 plus 2019-nCov IgG | EUROIMMUN anti-SARS-CoV-2 IgA | EUROIMMUN anti-SARS-CoV-2 IgG | EDI novel COVID-19 IgM | EDI novel COVID-19 IgG |
|---|---|---|---|---|---|---|
| Respiratory patients (n=55) | ||||||
| Adenovirus (5) | 2 | |||||
| Influenza A (20) | 3 | 1 | 2 | 1 | ||
| Influenza B (19) | 5 | |||||
| Parainfluenza (5) | 2 | 1 | 1 | |||
| RSV (5) | 1 | 3 | ||||
| Mycoplasma pneumoniae (5) | 3 | 1 | ||||
| Bordetella pertussis (5) | 4 | 1 | ||||
| Potential cross-reacting sera (n=35) | ||||||
| CMV (10) | 2 | 1 | 2 | |||
| EBV (10) | 4 | 1 | ||||
| Parvovirus (5) | 1 | |||||
| Rheumatoid factor (5) | 2 | 2 | ||||
| Antinuclear antibody (5) | 2 | 1 | ||||
| Healthy population (n=48) | 1 | 1 | 21 | 2 | 1 | 2 |
| Total specificity (n=138) Confidence interval |
98.6 [94.9, 99.2] |
97.8 [93.8, 99.6] |
60.9, [52.2, 69.1] |
94.2 [88.9, 97.5] |
94.9 [89.8, 97.9] |
93.5 [88.0, 96.9] |
CMV, cytomegalovirus; EBV, Epstein–Barr virus; RSV, respiratory syncytial virus.